Amyotrophic lateral sclerosis (ALS)

What changes during this transition

Amyotrophic lateral sclerosis is a defined clinical disease — progressive degeneration of upper and lower motor neurons, with selective motor system involvement that distinguishes it from generalized neurodegenerative disease, and a median survival of 2-5 years from symptom onset (with substantial variation — bulbar-onset typically faster, limb-onset slower, the C9orf72 hexanucleotide repeat expansion familial subset variable). The diagnostic frame is ALS-specialist-neurologist-led using the Awaji-Shima electrodiagnostic criteria (preferred over the older El Escorial criteria for sensitivity), and the ALS-mimic rule-out is editorially load-bearing because some mimics are treatable: multifocal motor neuropathy (responds to IVIG), cervical or lumbar spondylotic radiculomyelopathy (structural), inclusion-body myositis, Kennedy disease / spinobulbar muscular atrophy (X-linked, slower course), primary lateral sclerosis (related but distinct upper-motor-neuron-only phenotype with longer survival), or hexosaminidase A deficiency in young-onset cases. Sporadic ALS accounts for roughly 90% of cases; familial ALS the remaining 10%, with the C9orf72 hexanucleotide repeat expansion as the largest familial subset (~40% of familial, ~5-10% of sporadic in some populations), followed by SOD1 (~20% of familial, ~2% of all ALS — editorially load-bearing because tofersen has a registered targeted therapy for this subset), TARDBP encoding TDP-43, FUS, and additional rarer genes. Bulbar-onset vs limb-onset characterization matters editorially because bulbar-onset is typically faster-progressing with different supportive-care timing. Standard-of-care is established cross-jurisdictionally and centers on a small set of pharmacologic anchors layered on multidisciplinary clinic care. Riluzole (Rilutek, since FDA approval in 1995) is the foundation — a glutamate-release-inhibiting compound with a modest but consistently replicated ~3-month median survival benefit, the only pharmacologic with a consistently replicated motor-neuron-survival signal across three decades. Edaravone (Radicava) carries a multi-jurisdictional approval timeline that is editorially relevant: Japan's PMDA approved edaravone for ALS in June 2015 (nearly two years before the FDA Radicava IV approval in May 2017), with the Radicava ORS oral formulation following at FDA in May 2022 — the Japanese cross-jurisdictional clinical experience predates the US approval. AMX0035 (Relyvrio, sodium phenylbutyrate / taurursodiol combination) was FDA-approved September 2022 on the basis of the CENTAUR Phase 2 trial showing slowed ALSFRS-R decline, then voluntarily withdrawn from the US market by Amylyx in April 2024 after the confirmatory PHOENIX Phase 3 trial failed to meet its primary endpoint — this withdrawal is recent, editorially load-bearing context for any user diagnosed between September 2022 and April 2024 who started AMX0035 during the approval window. Tofersen (Qalsody) was FDA-approved April 2023 under accelerated approval for SOD1-mutant ALS specifically — an intrathecally-administered antisense oligonucleotide that suppresses SOD1 protein production. SOD1 genotyping is therefore time-sensitive in any user with familial ALS or family history. Multidisciplinary clinic care (neurology, PT, OT, SLP, respiratory therapy, nutrition, social work, palliative care) is itself associated with survival benefit independent of any individual pharmacotherapy. NIV (non-invasive ventilation, typically BiPAP) initiation guided by FVC, MIP, and overnight oximetry meaningfully impacts survival and quality of life and is time-sensitive. PEG tube placement before significant weight loss and before respiratory function declines below FVC thresholds that raise procedural risk is consensus across AAN 2023 evidence-based guideline and ENCALS 2024 recommendations. AAC (augmentative and alternative communication) device planning before bulbar speech loss progresses is time-sensitive because device setup requires cognitive participation. Mobility equipment progression has its own timing. Advance care planning, palliative care involvement, and hospice consideration belong in the cognitive and communicative capacity window. The HEALEY ALS Platform Trial at Massachusetts General Hospital is the editorially load-bearing actionable enrollment route. Adaptive platform trials run multiple investigational compounds concurrently against a shared placebo arm, dramatically reducing the placebo burden per participant and accelerating readouts. HEALEY has enrolled and reported on pridopidine (a sigma-1 receptor agonist with reported preliminary signals), SLS-005 (trehalose), CNM-Au8, zilucoplan (terminated in HEALEY), ABBV-CLS-7262, and additional regimens. Trial enrollment is a defensible adjunct path. NurOwn (BrainStorm Cell Therapeutics, autologous bone-marrow-derived MSC-NTF) had mixed signals across its program — original Phase 3 missed primary endpoint, FDA September 2023 advisory committee voted against approval. Historical program failures: the IGF-1 LR3 Phase 3 trial program in the early 2000s failed primary endpoint despite the IGF-1 / motor-neuron-trophic-support rationale. Where Juno's library fits — narrowly and with deliberate non-elevation. No peptide in the library has a discovery-card-defensible ALS case. The five drafted substrate entries (SS-31, Cerebrolysin, NMN, BPC-157, Dihexa) exist for honest /ask answers when users probe specific compounds, not for browse elevation. SS-31's mitochondrial-protection biology is mechanistically interesting in ALS but Rule 6 non-propagation applies — the March 2025 Forzinity Barth syndrome FDA approval does not propagate to ALS. Cerebrolysin's registered dementia and stroke indications across 50+ jurisdictions do not propagate to motor-neuron disease without ALS-specific trial evidence. NMN's NAD+ biology is real and the neighboring NAD+ precursor nicotinamide riboside has had small exploratory ALS work, but neither has a Phase 2/3 ALS readout. BPC-157 is community-extrapolation only — Sikiric Zagreb gastric mucosal and tendon-ligament rodent corpus does not address motor-neuron biology. Dihexa is theoretical mechanism-only — no preclinical ALS program. The honest editorial frame: ALS multidisciplinary clinic coordination, the riluzole-edaravone-tofersen-when-SOD1 standard-of-care backbone, time-sensitive supportive-care planning, advance care planning while capacity exists, and HEALEY ALS Platform Trial enrollment drive outcomes; no peptide in the library substitutes.